RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Avadel Pharmaceuticals - Stock

Avadel Pharmaceuticals ROE 2024

Avadel Pharmaceuticals ROE

-1.83

Avadel Pharmaceuticals Dividend yield

Ticker

AVDL

ISIN

US05337M1045

WKN

A2DJR8

In 2024, Avadel Pharmaceuticals's return on equity (ROE) was -1.83, a -128.1% increase from the 6.5 ROE in the previous year.

Avadel Pharmaceuticals Aktienanalyse

What does Avadel Pharmaceuticals do?

Avadel Pharmaceuticals PLC is an Irish pharmaceutical company that focuses on the development, manufacturing, and marketing of pharmaceutical products. The company was founded in 1999 under the name Flamel Technologies and was renamed Avadel Pharmaceuticals in 2019 to support its rebranding strategy and expand its activities in the global market. Avadel's business model is based on the discovery and development of therapies for rare diseases and sleep-related disorders, as well as the manufacturing and marketing of generic drugs and specialty products. The company is divided into three main segments: specialty pharmaceuticals, generic pharmaceuticals, and the Pediarix division. Avadel's specialty pharmaceuticals segment focuses on developing drugs for patients with rare diseases such as Prader-Willi syndrome or narcolepsy. An example of an innovative product in this segment is Rekarbri, an ORP medication for the treatment of narcolepsy. It is the first drug in the EU specifically tailored to the specific needs of narcolepsy patients and has improved patients' quality of life. The generic pharmaceuticals segment of Avadel offers high-quality and cost-effective medications that treat commonly prescribed and everyday conditions such as pain, infections, depression, and anxiety disorders. Most products in this segment are manufactured in the USA and are available in many countries worldwide. Avadel's Pediarix division specializes in the development and manufacturing of children's medicines. This includes products for the treatment of attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). An example of a product from this segment is Reagila, a medication for the treatment of ADHD in children that is known for its improved efficacy and lower risk of side effects. Avadel also has a geographically distributed business structure that allows it to market its products worldwide. The company has a strong presence in the USA and is represented in Europe, Asia, and Australia. It has an impressive research and development infrastructure, including manufacturing facilities and research facilities, that allow it to meet the needs of its customers. Overall, Avadel Pharmaceuticals is a leading pharmaceutical company that focuses on researching new and innovative therapies for patients with rare diseases and sleep-related disorders. The company has demonstrated its ability to bring effective products to the market while maintaining the highest standards in quality assurance and customer service. It is expected that Avadel will continue to grow in the future and introduce new and innovative products to help its customers and patients worldwide. Avadel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Avadel Pharmaceuticals's Return on Equity (ROE)

Avadel Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Avadel Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Avadel Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Avadel Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Avadel Pharmaceuticals Stock

What is the ROE (Return on Equity) of Avadel Pharmaceuticals this year?

The ROE of Avadel Pharmaceuticals this year is -1.83 undefined.

How has the Return on Equity (ROE) of Avadel Pharmaceuticals developed compared to the previous year?

The ROE of Avadel Pharmaceuticals has increased by -128.1% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Avadel Pharmaceuticals?

A high ROE indicates that Avadel Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Avadel Pharmaceuticals?

A low ROE can indicate that Avadel Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Avadel Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Avadel Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Avadel Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Avadel Pharmaceuticals?

Some factors that can influence Avadel Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Avadel Pharmaceuticals pay?

Over the past 12 months, Avadel Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avadel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Avadel Pharmaceuticals?

The current dividend yield of Avadel Pharmaceuticals is .

When does Avadel Pharmaceuticals pay dividends?

Avadel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avadel Pharmaceuticals?

Avadel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Avadel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avadel Pharmaceuticals located?

Avadel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avadel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avadel Pharmaceuticals from 6/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/10/2024.

When did Avadel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/10/2024.

What was the dividend of Avadel Pharmaceuticals in the year 2023?

In the year 2023, Avadel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Avadel Pharmaceuticals pay out the dividend?

The dividends of Avadel Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Avadel Pharmaceuticals

Our stock analysis for Avadel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avadel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.